AU2022260813A1 - Transdermal pharmaceutical formulations for the treatment of chronic pain - Google Patents

Transdermal pharmaceutical formulations for the treatment of chronic pain Download PDF

Info

Publication number
AU2022260813A1
AU2022260813A1 AU2022260813A AU2022260813A AU2022260813A1 AU 2022260813 A1 AU2022260813 A1 AU 2022260813A1 AU 2022260813 A AU2022260813 A AU 2022260813A AU 2022260813 A AU2022260813 A AU 2022260813A AU 2022260813 A1 AU2022260813 A1 AU 2022260813A1
Authority
AU
Australia
Prior art keywords
transdermal
pain
pharmaceutical composition
once
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022260813A
Other languages
English (en)
Inventor
Tamanna LATHER
Fotios M. Plakogiannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of AU2022260813A1 publication Critical patent/AU2022260813A1/en
Assigned to Pike Therapeutics Inc. reassignment Pike Therapeutics Inc. Amend patent request/document other than specification (104) Assignors: PIKE THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022260813A 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain Abandoned AU2022260813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177981P 2021-04-22 2021-04-22
US63/177,981 2021-04-22
PCT/IB2022/053730 WO2022224184A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
AU2022260813A1 true AU2022260813A1 (en) 2023-10-26

Family

ID=83722736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022260813A Abandoned AU2022260813A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Country Status (8)

Country Link
US (1) US20220347151A1 (https=)
EP (1) EP4326252A4 (https=)
JP (1) JP2024514362A (https=)
CN (1) CN117545478A (https=)
AU (1) AU2022260813A1 (https=)
CA (1) CA3215685A1 (https=)
MX (1) MX2023012483A (https=)
WO (1) WO2022224184A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CN119896633A (zh) * 2025-01-17 2025-04-29 中国人民解放军空军军医大学 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
EP3538122B1 (en) * 2016-11-14 2025-03-26 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US10966946B2 (en) * 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
CA3060926A1 (en) * 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US20200197359A1 (en) * 2018-09-17 2020-06-25 Cody D. Freeze Cannabinoid and Terpene-Infused Topical Cream
US12403114B2 (en) * 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2020263643A1 (en) * 2019-06-28 2020-12-30 Nexzol Pharma, Inc. Transdermal formulations
AU2020358869A1 (en) * 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4041209A4 (en) * 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) * 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂

Also Published As

Publication number Publication date
US20220347151A1 (en) 2022-11-03
JP2024514362A (ja) 2024-04-01
WO2022224184A1 (en) 2022-10-27
EP4326252A4 (en) 2025-03-12
CA3215685A1 (en) 2022-10-27
EP4326252A1 (en) 2024-02-28
CN117545478A (zh) 2024-02-09
MX2023012483A (es) 2023-11-03

Similar Documents

Publication Publication Date Title
US20250248948A1 (en) Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
US12186280B2 (en) Pharmaceutical composition and method for treating seizure disorders
EP4045024A1 (en) Transdermal delivery of cannabidiol
US12121617B2 (en) Transdermal delivery of cannabidiol
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
AU2022260813A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain
JP2022550569A (ja) ドロナビノールの経皮送達
WO2022215030A1 (en) Pharmaceutical composition and method for treating seizure disorders
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PIKE THERAPEUTICS INC.

Free format text: FORMER NAME(S): PIKE THERAPEUTICS, INC.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period